Innate Pharma SA Announces DSMB Positive Review of Ongoing EffiKIR Phase II Trial with Lirilumab
Innate Pharma SA announced that the Data and Safety Monitoring Board (DSMB) completed its first assessment of the EffiKIR study and unanimously recommended continuation of the trial without modification. EffiKIR is a double-blind placebo-controlled randomized Phase II trial of lirilumab as maintenance treatment in elderly patients with Acute Myeloid Leukemia (AML) in first complete remission. The assessment was based on a safety analysis pre-planned for when the first 30 patients would be treated with a minimum of two cycles of therapy. A DSMB is a committee of independent clinical research experts who review data in ongoing clinical trials with particular attention to safety. DSMBs are customarily established for large randomized multisite studies.
- Share this
- Digg this